Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized observer-blind study of three H1N1 pandemic influenza vaccine schedules in healthy adolescents
2009-016268-35Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2009
- Modality
- Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Q-Pan H1N1 vaccine and AS03 in influenza A virus infection (H1N1) (3 arms), sponsored by GSK. Primary endpoints: Humoral immune response in terms of HI antibodies, Seroconversion rate and 2 more. Started Nov 2009; status: completed.
02
Drugs
Q-Pan H1N1 vaccineAS03
03
Conditions
influenza A virus infection (H1N1)
Beyond the preview
Go deeper on 2009-016268-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016268-35.